PriceTargets.com logo

Revolution Medicines - RVMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $78.50
  • Forecasted Upside: 0.03%
  • Number of Analysts: 18
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 14 Buy Ratings
  • 3 Strong Buy Ratings
$78.48 As of 12/4/2025 05:00 PM ET
▲ +0.79 (1.02%)

This chart shows the closing price for RVMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revolution Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVMD

Analyst Price Target is $78.50
▲ +0.03% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $78.50, with a high forecast of $99.00 and a low forecast of $70.00. The average price target represents a 0.03% upside from the last price of $78.48.

This chart shows the closing price for RVMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 18 polled investment analysts is to buy stock in Revolution Medicines. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 2 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 3 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 3 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2025Wolfe ResearchInitiated CoverageOutperform$75.00
11/17/2025Wolfe ResearchUpgradeStrong-Buy
11/6/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$71.00 ➝ $82.00
11/6/2025Needham & Company LLCBoost TargetBuy ➝ Buy$66.00 ➝ $72.00
11/6/2025WedbushBoost TargetOutperform ➝ Outperform$77.00 ➝ $80.00
11/6/2025HC WainwrightBoost TargetBuy ➝ Buy$72.00 ➝ $73.00
11/3/2025Royal Bank Of CanadaInitiated CoverageOutperform$77.00
10/21/2025MizuhoInitiated CoverageOutperform$90.00
10/20/2025MizuhoUpgradeStrong-Buy
10/17/2025National BanksharesSet Target$80.00
10/17/2025Raymond James FinancialBoost TargetStrong-Buy ➝ Strong-Buy$72.00 ➝ $76.00
10/17/2025WedbushReiterated RatingOutperform ➝ Outperform$77.00
10/15/2025Stifel NicolausInitiated CoverageBuy$85.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/12/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$65.00 ➝ $73.00
9/12/2025Raymond James FinancialInitiated CoverageStrong-Buy$72.00
9/11/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$67.00 ➝ $70.00
9/11/2025WedbushBoost TargetOutperform ➝ Outperform$73.00 ➝ $77.00
9/11/2025Needham & Company LLCBoost TargetBuy ➝ Buy$56.00 ➝ $66.00
9/5/2025Truist FinancialInitiated CoverageBuy$99.00
8/18/2025Piper SandlerInitiated CoverageOverweight ➝ Overweight$75.00
8/18/2025Lifesci CapitalInitiated CoverageOutperform$80.00
8/15/2025Wells Fargo & CompanyInitiated CoverageOverweight$67.00
8/7/2025Needham & Company LLCLower TargetBuy ➝ Buy$57.00 ➝ $56.00
7/15/2025The Goldman Sachs GroupInitiated CoverageBuy$65.00
6/25/2025GuggenheimReiterated RatingBuy ➝ Buy$80.00
6/24/2025WedbushReiterated RatingOutperform$67.00 ➝ $73.00
6/24/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$57.00
5/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/8/2025WedbushReiterated RatingOutperform$67.00
5/8/2025OppenheimerBoost TargetOutperform ➝ Outperform$70.00 ➝ $75.00
5/8/2025GuggenheimLower TargetBuy ➝ Buy$87.00 ➝ $80.00
5/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
4/28/2025WedbushReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.00
4/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
4/1/2025Stifel NicolausLower TargetBuy ➝ Buy$78.00 ➝ $64.00
3/3/2025HC WainwrightBoost TargetBuy ➝ Buy$72.00 ➝ $73.00
2/27/2025WedbushReiterated RatingOutperform$67.00
2/27/2025Stifel NicolausLower TargetBuy ➝ Buy$80.00 ➝ $78.00
2/27/2025Needham & Company LLCLower TargetBuy ➝ Buy$60.00 ➝ $59.00
1/8/2025UBS GroupBoost TargetBuy ➝ Buy$65.00 ➝ $71.00
12/4/2024HC WainwrightBoost TargetBuy ➝ Buy$64.00 ➝ $72.00
12/3/2024GuggenheimBoost TargetBuy ➝ Buy$82.00 ➝ $87.00
12/3/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$63.00 ➝ $71.00
12/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$68.00 ➝ $68.00
12/2/2024WedbushReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00
11/7/2024HC WainwrightBoost TargetBuy ➝ Buy$62.00 ➝ $64.00
11/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$61.00 ➝ $68.00
11/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$54.00 ➝ $63.00
11/7/2024Piper SandlerBoost TargetOverweight ➝ Overweight$57.00 ➝ $70.00
10/28/2024GuggenheimBoost TargetBuy ➝ Buy$72.00 ➝ $82.00
10/28/2024OppenheimerBoost TargetOutperform ➝ Outperform$55.00 ➝ $60.00
10/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00 ➝ $61.00
10/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$61.00 ➝ $61.00
9/27/2024BarclaysBoost TargetOverweight ➝ Overweight$54.00 ➝ $60.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$56.00 ➝ $56.00
8/8/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$55.00 ➝ $54.00
8/8/2024WedbushReiterated RatingOutperform ➝ Outperform$59.00 ➝ $59.00
8/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$62.00 ➝ $61.00
7/18/2024BarclaysBoost TargetOverweight ➝ Overweight$52.00 ➝ $54.00
7/16/2024OppenheimerBoost TargetOutperform ➝ Outperform$45.00 ➝ $55.00
7/16/2024Bank of AmericaBoost TargetBuy ➝ Buy$48.00 ➝ $55.00
7/16/2024Needham & Company LLCBoost TargetBuy ➝ Buy$46.00 ➝ $62.00
7/16/2024HC WainwrightBoost TargetBuy ➝ Buy$44.00 ➝ $56.00
7/12/2024BarclaysInitiated CoverageOverweight$52.00
7/8/2024Jefferies Financial GroupInitiated CoverageBuy$63.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$44.00
5/9/2024WedbushBoost TargetOutperform ➝ Outperform$42.00 ➝ $46.00
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00
4/12/2024OppenheimerBoost TargetOutperform ➝ Outperform$43.00 ➝ $45.00
4/10/2024Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$36.00 ➝ $48.00
4/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$36.00 ➝ $46.00
3/11/2024Piper SandlerInitiated CoverageOverweight$43.00
2/27/2024WedbushBoost TargetOutperform ➝ Outperform$41.00 ➝ $42.00
1/16/2024Raymond James FinancialBoost TargetOutperform ➝ Outperform$30.00 ➝ $36.00
1/5/2024Bank of AmericaUpgradeNeutral ➝ Buy$31.00 ➝ $34.00
1/4/2024WedbushInitiated CoverageOutperform$41.00
12/20/2023UBS GroupInitiated CoverageBuy$40.00
11/16/2023Raymond James FinancialInitiated CoverageOutperform$30.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $28.00
11/7/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$47.00 ➝ $39.00
11/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$36.00
10/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
10/23/2023OppenheimerBoost TargetOutperform ➝ Outperform$40.00 ➝ $43.00
10/23/2023Needham & Company LLCBoost TargetBuy ➝ Buy$34.00 ➝ $36.00
10/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$34.00
9/21/2023Stifel NicolausBoost TargetBuy ➝ Buy$37.00 ➝ $47.00
8/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $34.00
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
8/2/2023OppenheimerBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00
8/2/2023Needham & Company LLCBoost TargetBuy ➝ Buy$31.00 ➝ $35.00
5/9/2023JPMorgan Chase & Co.Lower Target$38.00 ➝ $35.00
4/12/2023HC WainwrightReiterated RatingBuy$32.00
3/1/2023The Goldman Sachs GroupBoost TargetNeutral$20.00 ➝ $23.00
2/28/2023GuggenheimReiterated RatingBuy$38.00
2/28/2023Needham & Company LLCBoost TargetBuy$32.00 ➝ $38.00
2/28/2023OppenheimerBoost TargetOutperform$30.00 ➝ $35.00
2/28/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00 ➝ $38.00
12/14/2022Needham & Company LLCInitiated CoverageBuy$31.00
12/8/2022HC WainwrightBoost TargetBuy$30.00 ➝ $32.00
11/8/2022HC WainwrightLower TargetBuy$37.00 ➝ $30.00
10/20/2022OppenheimerInitiated CoverageOutperform$30.00
8/17/2022HC WainwrightLower TargetBuy$40.00 ➝ $37.00
8/10/2022Leerink PartnersLower TargetOutperform$31.00 ➝ $30.00
5/20/2022Bank of AmericaInitiated CoverageNeutral$24.00
5/9/2022Leerink PartnersReiterated RatingOutperform
3/1/2022HC WainwrightBoost Target$38.00 ➝ $40.00
3/1/2022Stifel NicolausUpgradeHold ➝ Buy$36.00 ➝ $26.00
11/12/2021HC WainwrightBoost TargetBuy$31.00 ➝ $38.00
9/22/2021Stifel NicolausInitiated CoverageHold$34.00
8/17/2021HC WainwrightLower TargetBuy$55.00 ➝ $31.00
8/12/2021GuggenheimLower TargetBuy$52.00 ➝ $34.00
8/12/2021Leerink PartnersLower TargetOutperform$46.00 ➝ $38.00
8/12/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$49.00 ➝ $27.00
6/29/2021HC WainwrightReiterated RatingBuy$55.00
6/20/2021Leerink PartnersReiterated RatingBuy
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$49.00
5/11/2021Leerink PartnersLower TargetOutperform$55.00 ➝ $46.00
3/3/2021Leerink PartnersBoost TargetOutperform$46.00 ➝ $55.00
1/29/2021JPMorgan Chase & Co.Boost Target$33.00 ➝ $44.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 36 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 43 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 10 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/8/2025
  • 12 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 33 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 32 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 11 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 38 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 38 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Revolution Medicines logo
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $78.48
Low: $76.53
High: $79.06

50 Day Range

MA: $59.75
Low: $43.92
High: $78.48

52 Week Range

Now: $78.48
Low: $29.17
High: $79.07

Volume

2,132,765 shs

Average Volume

2,278,929 shs

Market Capitalization

$15.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Revolution Medicines?

The following Wall Street research analysts have issued stock ratings on Revolution Medicines in the last twelve months: Guggenheim, HC Wainwright, JPMorgan Chase & Co., Lifesci Capital, Mizuho, National Bankshares, Inc., Needham & Company LLC, Oppenheimer Holdings, Inc., Piper Sandler, Raymond James Financial, Inc., Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wedbush, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for RVMD.

What is the current price target for Revolution Medicines?

0 Wall Street analysts have set twelve-month price targets for Revolution Medicines in the last year. Their average twelve-month price target is $78.50, suggesting a possible upside of 0.0%. Truist Financial Corporation has the highest price target set, predicting RVMD will reach $99.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $70.00 for Revolution Medicines in the next year.
View the latest price targets for RVMD.

What is the current consensus analyst rating for Revolution Medicines?

Revolution Medicines currently has 1 sell rating, 14 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVMD will outperform the market and that investors should add to their positions of Revolution Medicines.
View the latest ratings for RVMD.

What other companies compete with Revolution Medicines?

Other companies that are similar to Revolution Medicines include argenex, Takeda Pharmaceutical, Insmed, BeOne Medicines and Teva Pharmaceutical Industries. Learn More about companies similar to Revolution Medicines.

How do I contact Revolution Medicines' investor relations team?

Revolution Medicines' physical mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The company's listed phone number is 650-481-6801 and its investor relations email address is [email protected]. The official website for Revolution Medicines is www.revmed.com. Learn More about contacing Revolution Medicines investor relations.